Mesenchymal Cell News Volume 7.32 | Aug 18 2015

Density-Dependent Metabolic Heterogeneity in Human Mesenchymal Stem Cells
Researchers investigated the metabolic profiles of different subpopulations of human mesenchymal stem cell (hMSC) by testing the hypothesis that the clonogenic hMSC subpopulation, which is selectively enriched in clonal density and low density culture, possesses a metabolic phenotype that differs from that of hMSC in medium- or high-density. [Stem Cells] Abstract

Mechano Growth Factor E Peptide Promotes Rat Bone Marrow-Derived Mesenchymal Stem Cell Migration through CXCR4-ERK1/2
The authors determined that mechano growth factor (MGF)-25E induced the migration of rat bone marrow-derived mesenchymal stem cells (rMSCs) by modulating CXCR4 to activate the extracellular signal-regulated kinase 1/2 (ERK1/2) pathway. The analysis of the Young’s modulus and F-actin remodeling indicated that MGF-25E increased the stiffness and the F-actin polymerization of rMSCs through the activation of the CXCR4-ERK1/2 pathway. [Growth Factors] Abstract

Osteogenic Differentiation and Proliferation of Bone Marrow-Derived Mesenchymal Stromal Cells on PDLLA+BMP-2-Coated Titanium Alloy Surfaces
Investigators compared the osteogenic differentiation and proliferation of hMSC on native polished vs. sandblasted titanium surfaces (TS) and tested their behavior on pure poly-D,L-lactide (PDLLA) coated as well as PDLLA+rhBMP-2 coated TS. [J Biomed Mater Res A] Abstract

Direct Intercellular Communications Dominate the Interaction between Adipose-Derived MSCs and Myofibroblasts against Cardiac Fibrosis
In order to decipher the potential mechanism of mesenchymal stem cell (MSC) therapy for cardiac fibrosis, researchers investigated the interplay between MSCs and cardiac myofibroblasts using interactive co-culture method, with comparison to paracrine approaches, namely treatment by MSC conditioned medium and gap co-culture method. [Protein Cell] Full Article

Role of C-Jun N-Terminal Kinase in the Osteogenic and Adipogenic Differentiation of Human Adipose-Derived Mesenchymal Stem Cells
Scientists explored the possible role of JNKs in osteogenesis and adipogenesis of adipose-derived mesenchymal stem cells. Inhibition of the JNK signaling pathway using SP600125 blocked osteogenic differentiation in a dose-dependent manner, which was revealed by an ALP activity assay, extracellular calcium deposition detection, and expression of osteogenesis-relative genes via RT-PCR and real-time PCR. [Exp Cell Res] Abstract

Peroxisome Proliferator-Activated Receptor Gamma Promotes Mesenchymal Stem Cells to Express Connexin43 via the Inhibition of TGF-β1/Smads Signaling in a Rat Model of Myocardial Infarction
The authors hypothesized that activation of peroxisome proliferator-activated receptor-γ enhanced mesenchymal stem cell survival and their therapeutic efficacy via upregulating the expression of connexin43. [Stem Cell Rev] Abstract

Assessment of Long-Term Safety and Efficacy of Intranasal Mesenchymal Stem Cell Treatment for Neonatal Brain Injury in the Mouse
Researchers assessed whether intranasal mesenchymal stem cell (MSC) treatment after hypoxia-ischemia induces neoplasia in the brain or periphery at 14 months. Furthermore, the long-term effects of MSCs on behavior and lesion size were determined. [Ped Res] Abstract

Research Using Mesenchymal Stem/Stromal Cells: Quality Metric towards Developing a Reference Material
Establishing more than minimal criteria to define mesenchymal stem/stromal cells (MSCs) would help understand best protocols to isolate, propagate and deliver MSCs. Developing a calibration standard, a database and a set of functional tests would be a better quality metric for MSCs. The authors discuss the importance of selecting a standard, issues associated with coming up with such a standard and how these issues can be mitigated. [Cytotherapy] Abstract

Visit our reviews page to see a complete list of reviews in the mesenchymal cell research field.

Stemedica Awarded U.S. Patent for Transgenic Therapeutic Stem Cells
Stemedica Cell Technologies Inc. received United States Patent No. 9080184 entitled “Transgenic Therapeutic Stem Cells and Methods for Their Use and Manufacture.” [Stemedica Cell Technologies, Inc.] Press Release

From our sponsor: Want to learn more about the intestinal epithelium? Request a free wallchart from Cell.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mesenchymal cell community.

Postdoctoral Biologist/Cytogeneticist Researcher – Genomic Stability of Cultured HSCs and MSCs (University of Crete)

Professorship – Cellular and/or Molecular Biology and Immunology (Nanjing University)

Cellular Therapy Faculty (University of California, San Diego)

Cell Biology Lab Manager (Harvard Apparatus Regenerative Technology)

Science Writer (Houston Methodist Research Institute)

Scientific Writer – Stem Cells and Regenerative Medicine (University of Washington)

Postdoctoral Fellow – Stem Cell Biology (INSERM)

Postdoctoral Position – Stem Cells (Technion – Israel Institute of Technology)

Postdoctoral Fellow/Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.